Jaguar Health, Inc.
28.7.2021 14:31:39 CEST | ACCESS Newswire | Press release
Registration link for webcast appears below
SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, and member of the board of directors of Napo EU S.p.A., will be aired during an investor webcast tomorrow (Thursday, July 29, 2021) at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., which, with Dragon SPAC S.p.A., recently announced the closing of the financing of Dragon SPAC for gross proceeds of approximately 8,830,000 euros. The registration link for the webcast appears below.
Participation Instructions for Webcast
When: Thursday, July 29, 2021, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that an investor webcast will take place July 29, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/657270/REMINDER-FROM-JAGUAR-HEALTH-Innovators-with-Jane-King-Interview-with-Lisa-Conte-to-Air-During-Jaguar-Investor-Webcast-on-Thursday-July-29-2021-at-830-AM-Eastern-to-Provide-Business-Updates
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks21.4.2026 17:00:00 CEST | Press release
From edge inference to NVIDIA STX, purpose-built KV cache infrastructure for consistent performance at scale. SUNNYVALE, CA / ACCESS Newswire / April 21, 2026 / Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026. As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM.
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks21.4.2026 17:00:00 CEST | Press release
From edge inference to NVIDIA STX, purpose-built KV cache infrastructure for consistent performance at scale. SUNNYVALE, CA / ACCESS Newswire / April 21, 2026 / Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026. As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM.
87% of HR Leaders Have Conducted or Plan Layoffs in 2026. New LHH Research Reveals How Integrated Outplacement and Targeted Redeployment Protect Future Talent and Support Those Who Must Leave21.4.2026 14:07:00 CEST | Press release
Only 19% of employees recognize redeployment programs that 77% of HR leaders say exist, revealing a critical visibility gap that prevents organizations from retaining future-critical talent and fulfilling their duty of care to departing employees. NEW YORK CITY, NY / ACCESS Newswire / April 21, 2026 / New research from LHH, a global talent solutions provider and business unit of the Adecco Group, finds that 87% of HR leaders say their organization has already conducted or is planning layoffs in the next 12 months, driven by skills displacement, AI transformation, and shifting market demands. At the same time, 62% of employers track rehiring costs and nearly three quarters of those organizations acknowledge that rehiring costs are more than targeted redeployment and mobility. The findings, published in LHH's The Mobility Breakdown: Redeployment and Outplacement Trends Report reveal that as workforce restructuring becomes continuous, most organizations lack integrated outplacement and ta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom